Intense competition currently rules the vendor landscape of the global human reproductive technologies market. Significant presence of generic manufacturers such as Watson Pharmaceuticals Inc. (now Actavis, Inc.), Teva Pharmaceuticals, and Par Pharmaceuticals poses a tough challenge for the branded drugs manufacturers such as Bayer AG, Merck & Co., Inc., and Merck Serono.
Transparency Market Research (TMR) finds that the presence of blockbuster drugs as their generic counterparts in the same drug class fuels competition for product differentiation. Competition prevailing in the global human reproductive technologies market is thus expected to remain high through the forecast period between 2013 and 2019.
According to TMR, the global human reproductive technologies market stood at US$23.85 bn in 2012. Exhibiting a moderate CAGR of 2.3%, the market is expected to reach US$28.42 bn by the end of 2019. Despite North America emerging as dominant regional market in 2012, Asia Pacific is likely to demonstrate the leading CAGR of 3.5% during the aforementioned forecast period. By technology, the contraceptive devices segment is likely to remain the leading segment in the market reporting a CAGR of 5.7% between 2013 and 2019.
Delayed Family Planning to Fuel Demand for Human Reproductive Technologies
Various factors have been aiding growth witnessed by the market over the last few years. However, age has remained one of the primary factors affecting a patient’s ability to conceive, thereby creating demand for human reproductive technologies. “As population in general become highly focused on their career, family planning is taking a backseat. Such delayed family planning decisions have been a primary cause of infertility,” observes the TMR report’s author. According to the WHO, the prevalence of infertility around the world is quite visible, with nearly 10% to 15% of worldwide population being infertile. This has been creating demand for human reproductive technologies around the world.
Furthermore, lifestyle hazards such as pollution, stress, and smoking, the rising incidence of unwanted pregnancies, and favorable initiatives by governments promoting the use of contraceptive products across emerging nations augur well for the human reproductive technologies market.
Market to Gain Impetus from Rising Prevalence of Obesity
The increasing prevalence of obesity has been leading to infertility among both men and women. Obesity can cause menstrual irregularities and reduce conception rate in women. Furthermore, obesity is also considered a prime cause of reduced response to fertility treatment among both men and women. “The rising prevalence of obesity is thus directly related to high risk of miscarriage and thus contributes to maternal or perinatal complications, which in turn creates demand for human reproductive technologies,” said a lead TMR analyst.
Limited Insurance Coverage Inhibits Market’s Growth
Despite witnessing favorable growth worldwide, limited insurance coverage has emerged as a major concern threatening the market’s growth to an extent. The market is also witnessing hindrance from economic and social factors such as high cost of infertility treatment medications in developed countries, inadequate access to medicines and weak economic conditions in emerging economies, and religious bans. Besides these, knowledge regarding the side-effects associated with contraceptive drugs and devices
Rising Medical Tourism to Augment Market’s Growth in Forthcoming Years
The market is expected to gain impetus from the rising medical tourism. According to TMR, medical tourism for fertility treatment has remained one of the fastest growing segments in the global human reproductive technologies. Additionally, the market is gaining from the increasing government support. For instance, governments across developing countries are providing subsidies in artificial reproductive technologies (ART) to enable population afford fertility treatments, thus boosting the global human reproductive technologies market. The market is also expected to gain from the presence of a strong product pipeline for contraceptive drugs.
The findings of the review are based on information published by TMR in a report, titled “Human Reproductive Technologies Market - Global Industry Analysis, Size, Procedures, Growth, Trends and Forecast 2013 - 2019.”
The report segments the global human reproductive technologies market as:
Human Reproductive Technologies Market by Infertility Drugs
- Gonal-f (recombinant follitropin alfa)
- Follistim AQ (follitropin beta)
- AndroGel (testosterone)
- Testim (testosterone)
- Viagra (sildenafil citrate)
- Cialis (tadalafil)
- Levitra/Staxyn (vardenafil)
Human Reproductive Technologies Market, by Infertility Procedures
- In Vitro Fertilization (IVF)
- Intracytoplasmic Sperm Injection (ICSI)
- Zygote Intrafallopian Transfer (ZIFT)
- Gamete Intrafallopian Transfer (GIFT)
- Intrauterine Insemination (IUI)
Human Reproductive Technologies Market, by Contraceptive Technologies
- Oral Contraceptive Pills
- Contraceptive Injectables
- Topical Contraceptives
- Male Contraceptive Devices (Male Condoms)
- Female Contraceptive Devices
Major geographies analyzed under this research report are:
- North America
- Rest of the World
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453